[{"orgOrder":0,"company":"Encube Ethicals","sponsor":"Novum Pharmaceutical Research Services","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Permethrin","moa":"Voltage-sensitive sodium channel","graph1":"Dermatology","graph2":"Phase III","graph3":"Encube Ethicals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Encube Ethicals \/ Novum Pharmaceutical Research Services","highestDevelopmentStatusID":"10","companyTruncated":"Encube Ethicals \/ Novum Pharmaceutical Research Services"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Novum Pharmaceutical Research Services","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Permethrin","moa":"Voltage-sensitive sodium channel","graph1":"Dermatology","graph2":"Phase III","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Novum Pharmaceutical Research Services","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Novum Pharmaceutical Research Services"},{"orgOrder":0,"company":"InfectoPharm Drugs and Consilium","sponsor":"Winicker Norimed GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Permethrin","moa":"Voltage-sensitive sodium channel","graph1":"Dermatology","graph2":"Phase III","graph3":"InfectoPharm Drugs and Consilium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"InfectoPharm Drugs and Consilium \/ Winicker Norimed GmbH","highestDevelopmentStatusID":"10","companyTruncated":"InfectoPharm Drugs and Consilium \/ Winicker Norimed GmbH"},{"orgOrder":0,"company":"InfectoPharm Drugs and Consilium","sponsor":"Winicker Norimed GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Permethrin","moa":"Voltage-sensitive sodium channel","graph1":"Dermatology","graph2":"Phase III","graph3":"InfectoPharm Drugs and Consilium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InfectoPharm Drugs and Consilium \/ Winicker Norimed GmbH","highestDevelopmentStatusID":"10","companyTruncated":"InfectoPharm Drugs and Consilium \/ Winicker Norimed GmbH"},{"orgOrder":0,"company":"Saptalis pharm","sponsor":"Biorasi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Permethrin","moa":"Voltage-sensitive sodium channel","graph1":"Dermatology","graph2":"Phase III","graph3":"Saptalis pharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Saptalis pharm \/ Biorasi","highestDevelopmentStatusID":"10","companyTruncated":"Saptalis pharm \/ Biorasi"},{"orgOrder":0,"company":"Viatris","sponsor":"DPT Laboratories, Ltd | VYNE Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Permethrin","moa":"Voltage-sensitive sodium channel","graph1":"Dermatology","graph2":"Phase II","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Viatris \/ DPT Laboratories, Ltd | VYNE Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Viatris \/ DPT Laboratories, Ltd | VYNE Therapeutics"},{"orgOrder":0,"company":"Mayne Pharma Do Brasil Ltda","sponsor":"Biorasi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BRAZIL","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Permethrin","moa":"Voltage-sensitive sodium channel","graph1":"Dermatology","graph2":"Phase III","graph3":"Mayne Pharma Do Brasil Ltda","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Mayne Pharma Do Brasil Ltda \/ Biorasi","highestDevelopmentStatusID":"10","companyTruncated":"Mayne Pharma Do Brasil Ltda \/ Biorasi"}]

Find Clinical Drug Pipeline Developments & Deals for Tox21_300691

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Lead Product(s) : Permethrin

                          Therapeutic Area : Dermatology

                          Study Phase : Phase III

                          Sponsor : Novum Pharmaceutical Research Services

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Permethrin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Scabies.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          October 09, 2015

                          Lead Product(s) : Permethrin

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Novum Pharmaceutical Research Services

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Dr Reddy Company Banner

                          02

                          AllPack Indonesia
                          Not Confirmed
                          AllPack Indonesia
                          Not Confirmed

                          Details : Permethrin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Scabies.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          April 23, 2024

                          Lead Product(s) : Permethrin

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Winicker Norimed GmbH

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          AllPack Indonesia
                          Not Confirmed
                          AllPack Indonesia
                          Not Confirmed

                          Details : InfectoScab (Permethrin) is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Scabies.

                          Product Name : InfectoScab

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          March 24, 2021

                          Lead Product(s) : Permethrin

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Winicker Norimed GmbH

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          AllPack Indonesia
                          Not Confirmed
                          AllPack Indonesia
                          Not Confirmed

                          Details : Permethrin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Scabies.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 04, 2019

                          Lead Product(s) : Permethrin

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Biorasi

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          AllPack Indonesia
                          Not Confirmed
                          AllPack Indonesia
                          Not Confirmed

                          Details : Permethrin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Scabies.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 07, 2017

                          Lead Product(s) : Permethrin

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Novum Pharmaceutical Research Services

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          AllPack Indonesia
                          Not Confirmed
                          AllPack Indonesia
                          Not Confirmed

                          Details : Permethrin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Scabies.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 01, 2016

                          Lead Product(s) : Permethrin

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Biorasi

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          AllPack Indonesia
                          Not Confirmed
                          AllPack Indonesia
                          Not Confirmed

                          Details : Permethrin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Scabies.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          March 24, 2014

                          Lead Product(s) : Permethrin

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase II

                          Sponsor : DPT Laboratories, Ltd | VYNE Therapeutics

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank